S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Debra Laskin named to Forbes 2026 50 Over 50: Innovation list

Over four decades of scientific inquiry into toxicology and pharmacology have earned Dr. Debra L. Laskin a spot on the Forbes 2026 50 Over 50: Innovation list. The honor highlights her pioneering work on how the immune system reacts to chemical threats and the mechanisms driving organ injury.

Debra Laskin named to Forbes 2026 50 Over 50: Innovation list
Photo: Bio & News

Dr. Laskin, who serves as a Distinguished Professor and Chair of the Department of Pharmacology and Toxicology at Rutgers University, has built a career defined by extensive research into pulmonary and hepatic toxicology. Her findings have provided critical insights for developing medical countermeasures against hazardous substances, including mustard agents. With a portfolio exceeding 350 publications, she remains a central figure in shaping modern immunotoxicology.

Beyond her academic output, Laskin serves on the Expert Panel for Fragrance Safety, where she applies her expertise to the independent evaluation of fragrance ingredients. Donald V. Belsito, Chair of the Expert Panel, noted that her intellectual rigor and commitment to mentoring the next generation of scientists have significantly advanced the field. Her role on the panel involves interpreting complex data to ensure human health and environmental protection, a task she balances alongside her academic leadership at the Ernest Mario School of Pharmacy.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!